Carlos Gustavo Wambier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Experimental prostate cancer drug may improve COVID-19 survival

Experimental prostate cancer drug may improve COVID-19 survival
gulfnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulfnews.com Daily Mail and Mail on Sunday newspapers.

Carlos gustavo wambierKintor pharmaceuticalsJohn mccoy of applied biology incAlpert medical school of brown universityImage creditJohn mccoyApplied biologyAlpert medical schoolஆல்பர்ட் மருத்துவ பள்ளி ஆஃப் பழுப்பு பல்கலைக்கழகம்படம் கடன்ஜான் ம்க்காய்பயன்படுத்தப்பட்டது உயிரியல்ஆல்பர்ட் மருத்துவ பள்ளி

Prostate Cancer Drug Improves COVID-19 Survival in Trial

Prostate Cancer Drug Improves COVID-19 Survival in Trial
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Carlos gustavo wambierKintor pharmaceuticalsJohn mccoy of applied biology incAlpert medical school of brown universityJohn mccoyApplied biology incAlpert medical schoolஆல்பர்ட் மருத்துவ பள்ளி ஆஃப் பழுப்பு பல்கலைக்கழகம்ஜான் ம்க்காய்ஆல்பர்ட் மருத்துவ பள்ளி

Experimental prostate cancer drug may improve COVID-19 survival; younger patients report long lasting symptoms

Experimental prostate cancer drug may improve COVID-19 survival; younger patients report long lasting symptoms
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCarlos gustavo wambierNancy lapidKintor pharmaceuticalsTrinity collegeJohn mccoy of applied biology incAlpert medical school of brown universityNexu science communicationJohn mccoyApplied biologyAlpert medical schoolNature medicineBill berkrotஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்

TodayIR: Kintor s Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Re-sults in Treatment of Male and Female Patients

SUZHOU, China, Jan. 10, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment

Andy gorenKostenloser wertpapierhandelCarlos gustavo wambierJohn mccoyAdsuara cadegianiMarketing pressUs national institute of allergyLinks ministry of healthKintor pharmaceutical limitedTrial shows positive re sultsFemale patientsTrial shows positive resultsClinical trialOutcome scaleInfection diseasesFemale patients

Kintor s Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients

Share this article Share this article SUZHOU, China, Jan. 10, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr. Andy Goren and Dr. Flávio Adsuara Cadegiani, shows promising results in the treatment of COVID-19 female outpatients. This trial commenced the enrolment of 168 female patients on Nov, 2020 after receiving the encouraging results from male patients. Eligible female patients were randomized in a 2:1 ratio to receive either Proxalutamide + standard care (Proxalutamide arm) or Placebo + standard care (Control arm). The co-primary endpoints of the clinical trial are the percentage of subjects hospitalized with COVID-19 and the COVID-19 Ordinal Outcome Scale (a 8-point ordinal scale used by the US National Institute of Allergy and Infection Diseases, such as mechanical ventilation usage and

Andy gorenCarlos gustavo wambierJohn mccoyAdsuara cadegianiUs national institute of allergyMinistry of healthKintor pharmaceuticalPrnewswire kintor pharmaceutical limitedPharmaceutical limitedOutcome scaleInfection diseasesTong youzhiCov protocol pioneeredApplied biologyBrazilian scientists adoptedKintor pharmaceutical limited